The US Food and Drug Administration (FDA) has approved dupilumab for the treatment of chronic spontaneous urticaria (CSU) in patients aged 12 years and older who “remain symptomatic despite H1 ...

Please provide your email address to receive an email when new articles are posted on . Dupilumab was able to improve lichenification among patients aged 6 to 88 years with atopic dermatitis.

Dupilumab had previously been shown to be effective in the treatment of atopic dermatitis, but this research is the first to examine the drug's efficacy in children with atopic dermatitis and co ...

BOSTON -- Add-on dupilumab (Dupixent) significantly reduced itching and urticaria in patients with chronic spontaneous urticaria (CSU) whose symptoms were uncontrolled with H1-antihistamine therapy.

The researchers report that mean symptom domain scores were 59.3 for dupilumab versus 58.6 for placebo, mean activity scores were 66.3 versus 65.8, and mean impact domain scores were 38.2 versus 37.3.

At 52 weeks, patients receiving dupilumab vs. placebo had improved measures of quality of life and symptom burden. Through this study, researchers have confirmed findings from the BOREAS study.

Dupilumab significantly reduced exacerbations and improved lung function in adults with uncontrolled chronic obstructive pulmonary disease (COPD) and type 2 inflammation, based on data from more ...

Dupilumab is a human monoclonal antibody that blocks the receptor shared by interleukin-4 (IL-4) and IL-13, both of which are key to the development of type 2 inflammation in chronic obstructive ...

Dupilumab shows long-term efficacy across yearly seasons in patients with type 2 inflammatory asthma. Patients with type 2 inflammatory asthma, with and without evidence of allergic asthma ...

VANCOUVER, British Columbia -- Treatment with higher-exposure dupilumab (Dupixent) led to sustained improvements in the reduction of peak esophageal intraepithelial eosinophil counts among ...

This monoclonal antibody is the first biologic shown to improve clinical outcomes in COPD. “Dupilumab has the potential to impact the vicious cycle of exacerbations and lung function decline in ...